430 related articles for article (PubMed ID: 16227290)
1. Prophylactic alpha interferon treatment increases the therapeutic index of oncolytic vesicular stomatitis virus virotherapy for advanced hepatocellular carcinoma in immune-competent rats.
Shinozaki K; Ebert O; Suriawinata A; Thung SN; Woo SL
J Virol; 2005 Nov; 79(21):13705-13. PubMed ID: 16227290
[TBL] [Abstract][Full Text] [Related]
2. Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus.
Shinozaki K; Ebert O; Kournioti C; Tai YS; Woo SL
Mol Ther; 2004 Mar; 9(3):368-76. PubMed ID: 15006603
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats.
Ebert O; Shinozaki K; Huang TG; Savontaus MJ; García-Sastre A; Woo SL
Cancer Res; 2003 Jul; 63(13):3605-11. PubMed ID: 12839948
[TBL] [Abstract][Full Text] [Related]
4. Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV.
Shinozaki K; Ebert O; Woo SL
Hepatology; 2005 Jan; 41(1):196-203. PubMed ID: 15619242
[TBL] [Abstract][Full Text] [Related]
5. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
[TBL] [Abstract][Full Text] [Related]
6. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
[TBL] [Abstract][Full Text] [Related]
7. Treatment of multi-focal colorectal carcinoma metastatic to the liver of immune-competent and syngeneic rats by hepatic artery infusion of oncolytic vesicular stomatitis virus.
Shinozaki K; Ebert O; Woo SL
Int J Cancer; 2005 Apr; 114(4):659-64. PubMed ID: 15609320
[TBL] [Abstract][Full Text] [Related]
8. Variable deficiencies in the interferon response enhance susceptibility to vesicular stomatitis virus oncolytic actions in glioblastoma cells but not in normal human glial cells.
Wollmann G; Robek MD; van den Pol AN
J Virol; 2007 Feb; 81(3):1479-91. PubMed ID: 17108037
[TBL] [Abstract][Full Text] [Related]
9. Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates.
Jenks N; Myers R; Greiner SM; Thompson J; Mader EK; Greenslade A; Griesmann GE; Federspiel MJ; Rakela J; Borad MJ; Vile RG; Barber GN; Meier TR; Blanco MC; Carlson SK; Russell SJ; Peng KW
Hum Gene Ther; 2010 Apr; 21(4):451-62. PubMed ID: 19911974
[TBL] [Abstract][Full Text] [Related]
10. Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo.
Altomonte J; Wu L; Chen L; Meseck M; Ebert O; García-Sastre A; Fallon J; Woo SL
Mol Ther; 2008 Jan; 16(1):146-53. PubMed ID: 18071337
[TBL] [Abstract][Full Text] [Related]
11. Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer.
Ebert O; Shinozaki K; Kournioti C; Park MS; García-Sastre A; Woo SL
Cancer Res; 2004 May; 64(9):3265-70. PubMed ID: 15126368
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.
Liu YP; Steele MB; Suksanpaisan L; Federspiel MJ; Russell SJ; Peng KW; Bakkum-Gamez JN
Gynecol Oncol; 2014 Jan; 132(1):194-202. PubMed ID: 24246772
[TBL] [Abstract][Full Text] [Related]
13. Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells.
Altomonte J; Wu L; Meseck M; Chen L; Ebert O; Garcia-Sastre A; Fallon J; Mandeli J; Woo SL
Cancer Gene Ther; 2009 Mar; 16(3):266-78. PubMed ID: 18846115
[TBL] [Abstract][Full Text] [Related]
14. rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy.
Wu L; Huang TG; Meseck M; Altomonte J; Ebert O; Shinozaki K; García-Sastre A; Fallon J; Mandeli J; Woo SL
Hum Gene Ther; 2008 Jun; 19(6):635-47. PubMed ID: 18533893
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats.
Altomonte J; Braren R; Schulz S; Marozin S; Rummeny EJ; Schmid RM; Ebert O
Hepatology; 2008 Dec; 48(6):1864-73. PubMed ID: 19003878
[TBL] [Abstract][Full Text] [Related]
16. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity.
Obuchi M; Fernandez M; Barber GN
J Virol; 2003 Aug; 77(16):8843-56. PubMed ID: 12885903
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of interferon action. Interferon alpha inhibits vesicular stomatitis virus primary transcript accumulation in P1/eIF-2 alpha protein kinase-deficient human fibroblast cells.
Zhang XT; Samuel CE
J Biol Regul Homeost Agents; 1987; 1(4):157-65. PubMed ID: 2845723
[TBL] [Abstract][Full Text] [Related]
18. Cell Cycle Arrest in G
Bressy C; Droby GN; Maldonado BD; Steuerwald N; Grdzelishvili VZ
J Virol; 2019 Feb; 93(4):. PubMed ID: 30487274
[TBL] [Abstract][Full Text] [Related]
19. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.
Moerdyk-Schauwecker M; Shah NR; Murphy AM; Hastie E; Mukherjee P; Grdzelishvili VZ
Virology; 2013 Feb; 436(1):221-34. PubMed ID: 23246628
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma.
Shin EJ; Wanna GB; Choi B; Aguila D; Ebert O; Genden EM; Woo SL
Laryngoscope; 2007 Feb; 117(2):210-4. PubMed ID: 17204993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
